GO:0016404 15-hydroxyprostaglandin dehydrogenase (NAD+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0016404 defines the NAD+-dependent oxidation of the 15(S)-hydroxyl group of prostaglandins, the first committed step in prostaglandin inactivation.
• The enzyme is widely known as 15-PGDH and is encoded by HPGD in humans; it is a short-chain dehydrogenase/reductase that uses NAD+ as its cofactor.
• 15-PGDH activity controls prostaglandin E2 (PGE2) levels in tissues such as endometrium, muscle, bone, and tumors.
• Inhibition or loss of 15-PGDH raises PGE2 and has been linked to tissue repair, bone homeostasis, and rejuvenation of aged muscle.
• Altered 15-PGDH expression is observed in several cancers and in inflammatory or metabolic contexts, making it a candidate biomarker and therapeutic target.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect the causal roles of HPGD and its regulators in disease.
Description
GO:0016404, 15-hydroxyprostaglandin dehydrogenase (NAD+) activity, is a molecular function that catalyzes the NAD+-dependent oxidation of the 15(S)-hydroxyl group of prostaglandins to a 15-keto group, producing NADH and a 15-keto prostaglandin. This reaction is the first and rate-limiting step in the biological inactivation of prostaglandins such as PGE2, and it is therefore a central node in controlling prostaglandin signaling. The enzyme responsible is commonly called 15-PGDH and is encoded by the HPGD gene in humans. Because prostaglandins regulate inflammation, tissue repair, bone homeostasis, and cancer progression, the activity of 15-hydroxyprostaglandin dehydrogenase (NAD+) is of broad interest to researchers in physiology, immunology, and oncology. The QuickGO definition specifies the exact substrates and products: (5Z,13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate plus NAD+ yields (5Z,13E)-11-alpha-hydroxy-9,15-dioxoprost-13-enoate plus NADH and H+. This precise chemistry distinguishes it from other prostaglandin-metabolizing enzymes and makes it a tractable target for biochemical and genetic studies.
15-hydroxyprostaglandin dehydrogenase (NAD+) activity At A Glance
| GO ID | GO:0016404 |
|---|---|
| GO term | 15-hydroxyprostaglandin dehydrogenase (NAD+) activity |
| Ontology | molecular_function |
| Synonym | 15-OH-PGDH; 15-hydroxyprostaglandin dehydrogenase activity; NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type I); prostaglandin dehydrogenase activity |
| Major function | NAD+-dependent oxidation of the 15(S)-hydroxyl group of prostaglandins, initiating their inactivation |
| Cofactor | NAD+ (nicotinamide adenine dinucleotide, oxidized form) |
| Representative enzyme | 15-PGDH, encoded by HPGD in humans |
| Substrate example | (5Z,13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate (PGE2) |
| Product example | (5Z,13E)-11-alpha-hydroxy-9,15-dioxoprost-13-enoate (15-keto PGE2) |
What Is GO:0016404?
In simple terms, GO:0016404 describes an enzyme activity that switches off prostaglandin signals by removing a hydroxyl group from position 15 of the prostaglandin molecule using NAD+ as the oxidizing agent. The official definition states: Catalysis of the reaction: (5Z,13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate + NAD+ = (5Z,13E)-11-alpha-hydroxy-9,15-dioxoprost-13-enoate + NADH + H+. This activity is synonymous with 15-hydroxyprostaglandin dehydrogenase activity, 15-OH-PGDH, NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (type I), and prostaglandin dehydrogenase activity. It belongs to the molecular_function aspect of the Gene Ontology and is classified as an oxidoreductase acting on the CH-OH group of donors with NAD+ or NADP+ as acceptor.
Why Is 15-hydroxyprostaglandin dehydrogenase (NAD+) activity Important in Cell Biology?
15-hydroxyprostaglandin dehydrogenase (NAD+) activity is important because it sets the rate of prostaglandin inactivation and thereby controls the duration and intensity of prostaglandin signaling in virtually every tissue. Prostaglandins such as PGE2 are potent lipid mediators of inflammation, pain, fever, tissue repair, and bone remodeling, and their levels are tightly regulated by synthesis and degradation. By oxidizing the 15(S)-hydroxyl group, 15-PGDH converts active prostaglandins into inactive 15-keto metabolites, effectively acting as a brake on prostaglandin action. Consequently, changes in this activity influence processes as diverse as endometrial function, muscle regeneration, sensory nerve regulation of bone homeostasis, and tumor progression. Researchers therefore study GO:0016404 to understand how prostaglandin signals are terminated and to explore therapeutic strategies that modulate this enzyme in disease.
• Controls the half-life and steady-state levels of prostaglandins such as PGE2 in tissues.
• Regulates inflammation and tissue repair by limiting prostaglandin-driven signaling.
• Modulates aged muscle mass and strength; inhibition of 15-PGDH rejuvenates aged muscle in preclinical models.
• Participates in bone homeostasis through prostaglandin E2-mediated sensory nerve regulation.
• Is expressed in human endometrium, where it contributes to prostaglandin metabolism in reproductive physiology.
• Is implicated in cancer biology, including liver carcinogenesis linked to arachidonic acid metabolism.
• Represents a potential target in tumor microenvironment remodeling for immunotherapy.
• Provides a biochemical handle for measuring prostaglandin inactivation in cells and tissues.
• Serves as a paradigm for NAD+-dependent short-chain dehydrogenase/reductase enzymology.
• Offers a druggable node for conditions where raising or lowering prostaglandin tone is desirable.
Molecular Mechanism of 15-hydroxyprostaglandin dehydrogenase (NAD+) activity
Substrate recognition and binding
In simple terms: The enzyme grabs the prostaglandin molecule and holds it in place so it can be modified.
15-PGDH binds prostaglandins such as PGE2 in a hydrophobic substrate pocket, positioning the 15(S)-hydroxyl group for catalysis. The enzyme shows specificity for the 15(S) stereochemistry and for the prostaglandin backbone, which ensures that only the correct lipid is oxidized. This binding step is the first determinant of whether a prostaglandin will be inactivated.
NAD+ cofactor binding and hydride transfer
In simple terms: NAD+ acts as a molecular shuttle that accepts electrons from the prostaglandin.
The catalytic mechanism requires NAD+ as the oxidizing cofactor. The enzyme is a short-chain dehydrogenase/reductase that uses a Rossmann-fold to bind NAD+ and catalyzes hydride transfer from the 15(S)-hydroxyl group of the prostaglandin to the nicotinamide ring of NAD+, generating NADH. This oxidation converts the 15-hydroxyl to a 15-keto group, yielding the inactive 15-keto prostaglandin and releasing H+.
Product release and reaction reversibility
In simple terms: After the reaction, the modified prostaglandin and NADH leave the enzyme.
Following hydride transfer, the 15-keto prostaglandin product and NADH are released from the active site, allowing the enzyme to turnover. The reaction is described as an oxidoreduction and is generally considered to favor prostaglandin inactivation under physiological NAD+/NADH ratios. The reaction is reversible in principle, but in cells the rapid removal of 15-keto prostaglandins and reoxidation of NADH drives the oxidative direction.
Regulation of enzyme abundance and activity
In simple terms: Cells can make more or less of the enzyme, or change how active it is, to tune prostaglandin levels.
The activity of 15-hydroxyprostaglandin dehydrogenase (NAD+) is regulated at the level of HPGD expression and by post-translational mechanisms that influence enzyme stability and catalytic efficiency. In aged muscle, pharmacological inhibition of 15-PGDH increases prostaglandin levels and rejuvenates muscle mass and strength, showing that this activity is a tunable node in vivo. In cancer contexts, altered expression of prostaglandin-metabolizing enzymes, including 15-PGDH, is associated with changes in arachidonic acid metabolism and tumor progression.
Key Genes Involved in GO:0016404 15-hydroxyprostaglandin dehydrogenase (NAD+) activity
The following genes and proteins are directly or functionally linked to 15-hydroxyprostaglandin dehydrogenase (NAD+) activity and its biological roles.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HPGD | Encodes 15-PGDH, the NAD+-dependent enzyme that catalyzes GO:0016404 | Core gene for knockout, point-mutation, and overexpression studies of prostaglandin inactivation |
| PTGS1 | Cyclooxygenase 1, produces prostaglandin precursors that are substrates for 15-PGDH | Context for balancing prostaglandin synthesis and degradation |
| PTGS2 | Cyclooxygenase 2, inducible enzyme that increases prostaglandin synthesis | Frequently studied alongside HPGD to assess prostaglandin tone |
| PTGER1 | EP1 receptor for PGE2, mediates downstream signaling | Used to dissect receptor-specific effects of altered 15-PGDH activity |
| PTGER2 | EP2 receptor for PGE2, couples to cAMP signaling | Relevant to tissue repair and regeneration studies |
| PTGER3 | EP3 receptor for PGE2, modulates diverse signaling pathways | Helps interpret phenotypic changes when 15-PGDH is manipulated |
| PTGER4 | EP4 receptor for PGE2, promotes repair and immune modulation | Important in tumor microenvironment and immunotherapy research |
| ENO1 | Enolase 1, promotes liver carcinogenesis via YAP1-dependent arachidonic acid metabolism | Links metabolic reprogramming to prostaglandin pathways |
| YAP1 | Transcriptional co-activator downstream of ENO1 in arachidonic acid metabolism | Potential upstream regulator of prostaglandin-related genes |
| NAD+ | Essential cofactor for the oxidation reaction | Central to biochemical assays of 15-PGDH activity |
| PGE2 | Primary prostaglandin substrate whose inactivation is catalyzed by 15-PGDH | Key metabolite measured in functional studies |
| 15-keto PGE2 | Inactive product of the 15-PGDH reaction | Biomarker of 15-PGDH enzymatic activity |
| HPGD regulators | Proteins and pathways that control HPGD expression or stability | Candidate targets for modulating prostaglandin inactivation |
| Muscle stem cells | Respond to prostaglandin signals modulated by 15-PGDH inhibition | Model system for aged muscle rejuvenation |
| Sensory neurons | Regulate bone homeostasis via PGE2, indirectly linked to 15-PGDH activity | Neuro-bone axis research |
| Tumor microenvironment cells | Respond to prostaglandin remodeling in glioblastoma immunotherapy | Oncolytic virus and immunotherapy models |
How Is 15-hydroxyprostaglandin dehydrogenase (NAD+) activity Regulated?
The activity of 15-hydroxyprostaglandin dehydrogenase (NAD+) is regulated primarily through the expression level and stability of the HPGD gene product, as well as through the availability of NAD+ and substrate prostaglandins. In aged muscle, pharmacological inhibition of 15-PGDH increases prostaglandin levels and rejuvenates muscle mass and strength, demonstrating that this activity can be modulated in vivo to influence tissue regeneration. In cancer, altered expression of prostaglandin-metabolizing enzymes, including 15-PGDH, is associated with changes in arachidonic acid metabolism and tumor progression, suggesting that oncogenic pathways can indirectly regulate this activity. Prostaglandin E2 itself participates in tissue repair and regeneration, creating feedback that may influence 15-PGDH expression or activity. In bone homeostasis, sensory nerve regulation of PGE2 provides a physiological context in which 15-PGDH activity may be tuned. Endometrial expression of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase activity indicates hormonal or cycle-dependent regulation in reproductive tissues.
15-hydroxyprostaglandin dehydrogenase (NAD+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HPGD | Muscle aging and regeneration | HPGD knockout or inhibitor-treated aged mouse muscle |
| HPGD | Cancer metabolism and tumor progression | Cancer cell lines with HPGD overexpression or knockout |
| HPGD | Bone homeostasis via PGE2 | Sensory neuron-specific or bone-targeted perturbation models |
| HPGD | Endometrial prostaglandin metabolism | Human endometrial cell culture and primary tissue explants |
| PTGS2 | Inflammation and tissue repair | PTGS2/HPGD double perturbation in repair models |
Cancer and tumor metabolism
Altered prostaglandin metabolism is linked to cancer progression. ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism, a pathway that intersects with prostaglandin synthesis and degradation. In glioblastoma, retargeted oncolytic viruses engineered to remodel the tumor microenvironment highlight the therapeutic potential of manipulating prostaglandin pathways in immunotherapy. Because 15-PGDH inactivates prostaglandins, changes in its activity can influence tumor cell proliferation, inflammation, and immune evasion.
Muscle aging and regeneration
Inhibition of the prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength, establishing a direct link between GO:0016404 and age-related muscle decline. This finding suggests that pharmacological or genetic reduction of 15-PGDH activity could be a strategy to enhance muscle regeneration in older individuals. Prostaglandin E2, the substrate of 15-PGDH, plays a central role in tissue repair and regeneration, providing a mechanistic basis for these observations.
Bone homeostasis and neuro-bone axis
Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis, and 15-PGDH activity controls PGE2 levels. Dysregulation of this axis could contribute to bone loss or abnormal bone remodeling. Studying 15-hydroxyprostaglandin dehydrogenase (NAD+) activity in this context may reveal new approaches to bone disease.
Reproductive and endometrial biology
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase activity has been measured in human endometrium, where it likely contributes to the cyclical control of prostaglandin levels. Abnormal prostaglandin inactivation in reproductive tissues may be relevant to menstrual disorders, implantation failure, or other gynecological conditions. This makes the enzyme a subject of interest in reproductive physiology and pathology.
From 15-hydroxyprostaglandin dehydrogenase (NAD+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of HPGD increase prostaglandin levels and alter tissue repair? | HPGD knockout cell lines or mice |
| Which catalytic residues are required for 15-PGDH activity? | Point-mutation knock-in of HPGD catalytic residues |
| Can tagged 15-PGDH be used to measure protein interactions and localization? | Knock-in of an epitope- or fluorescent-tagged HPGD |
| Does overexpression of HPGD reduce prostaglandin-driven phenotypes? | HPGD overexpression cell lines and organoids |
| How does HPGD activity affect tumor microenvironment remodeling? | HPGD-modulated tumor cells in immunotherapy models |
| What is the effect of HPGD inhibition on aged muscle? | Pharmacological inhibition or genetic ablation in aged muscle models |
How to Study the 15-hydroxyprostaglandin dehydrogenase (NAD+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADH-coupled spectrophotometric assay | NADH production during prostaglandin oxidation | Enzyme kinetics and inhibitor screening |
| LC-MS/MS lipidomics | PGE2 and 15-keto PGE2 levels | Tissue and cell metabolite profiling |
| RNA-seq | HPGD and prostaglandin pathway gene expression | Transcriptomic analysis across conditions |
| Western blot | 15-PGDH protein abundance | Validation of expression changes |
| Immunohistochemistry | Tissue localization of 15-PGDH | Endometrial and tumor tissue studies |
| CRISPR knockout screening | Genes required for prostaglandin metabolism phenotypes | Functional genomics of 15-PGDH pathways |
| Proximity ligation assay | Protein-protein interactions of 15-PGDH | Interactome mapping |
| Organoid culture | Prostaglandin-dependent growth and repair | Tissue regeneration studies |
Biochemical activity assays
Enzymatic activity of 15-hydroxyprostaglandin dehydrogenase (NAD+) can be measured by monitoring NADH production or the conversion of PGE2 to 15-keto PGE2 using spectrophotometric, fluorometric, or mass spectrometry-based assays. These assays are the gold standard for confirming that a candidate enzyme or mutant retains GO:0016404 activity.
Gene expression and transcriptomics
RNA-seq and qPCR can quantify HPGD mRNA levels across tissues and conditions, revealing how expression of the enzyme is regulated in physiological and disease states. Transcriptomic profiling of prostaglandin pathway genes, including PTGS1, PTGS2, and HPGD, helps contextualize changes in prostaglandin metabolism.
Proteomics and interactomics
Mass spectrometry-based proteomics can measure 15-PGDH protein abundance and identify post-translational modifications or interaction partners. Affinity purification with tagged 15-PGDH can reveal proteins that regulate its stability or activity.
Metabolite profiling
Targeted lipidomics or LC-MS/MS can quantify PGE2 and its 15-keto metabolite, providing a direct readout of 15-PGDH activity in cells and tissues. Such measurements are essential for linking enzyme activity to biological outcomes.
How CRISPR Can Be Used to Study GO:0016404 15-hydroxyprostaglandin dehydrogenase (NAD+) activity
Knockout
CRISPR knockout of HPGD eliminates 15-hydroxyprostaglandin dehydrogenase (NAD+) activity, causing accumulation of prostaglandins such as PGE2. This model is used to test whether loss of the enzyme enhances tissue repair, alters muscle regeneration, or changes tumor growth. Knockout cell lines also serve as negative controls in enzymatic assays.
Point Mutation
Point mutations in HPGD can be introduced to test the requirement for specific catalytic residues or cofactor-binding motifs. Such models help distinguish loss of catalytic activity from loss of protein expression or scaffolding functions. They are valuable for structure-function studies of the short-chain dehydrogenase/reductase fold.
Knock-in
Knock-in of epitope tags, fluorescent proteins, or reporter cassettes into the HPGD locus enables real-time tracking of 15-PGDH expression and localization. Knock-in of disease-associated or engineered variants allows study of their effects on prostaglandin metabolism in a physiological context. This approach is also useful for generating reporter lines to screen for modulators of GO:0016404.
Overexpression
Overexpression of HPGD increases 15-hydroxyprostaglandin dehydrogenase (NAD+) activity and lowers prostaglandin levels, providing a gain-of-function counterpart to knockout. This model is used to test whether enhanced prostaglandin inactivation suppresses inflammation, tumor growth, or other phenotypes. Overexpression systems also facilitate biochemical purification of the enzyme.
How EDITGENE Supports 15-hydroxyprostaglandin dehydrogenase (NAD+) activity Research
Researchers studying 15-hydroxyprostaglandin dehydrogenase (NAD+) activity-related genes often need to determine whether a candidate gene is causally involved in prostaglandin metabolism, tissue repair, or cancer progression. EDITGENE provides publication-ready CRISPR cell models and screening services to accelerate this work.
Contact EDITGENE today to design your custom CRISPR model for 15-hydroxyprostaglandin dehydrogenase (NAD+) activity research.
Frequently Asked Questions About 15-hydroxyprostaglandin dehydrogenase (NAD+) activity
What is 15-hydroxyprostaglandin dehydrogenase (NAD+) activity?
It is the enzyme activity defined by GO:0016404 that uses NAD+ to oxidize the 15(S)-hydroxyl group of prostaglandins, converting them to inactive 15-keto metabolites.
What gene encodes 15-hydroxyprostaglandin dehydrogenase (NAD+) activity?
In humans, the enzyme is encoded by the HPGD gene, and the protein is commonly called 15-PGDH.
What reaction does GO:0016404 catalyze?
It catalyzes the NAD+-dependent conversion of (5Z,13E)-(15S)-11-alpha,15-dihydroxy-9-oxoprost-13-enoate to (5Z,13E)-11-alpha-hydroxy-9,15-dioxoprost-13-enoate, producing NADH and H+.
Why is 15-PGDH important for prostaglandin signaling?
It is the first and rate-limiting enzyme in prostaglandin inactivation, controlling the duration and intensity of prostaglandin signals such as PGE2.
What diseases are linked to 15-hydroxyprostaglandin dehydrogenase (NAD+) activity?
It has been linked to muscle aging, cancer metabolism, bone homeostasis, and endometrial biology through its control of prostaglandin levels.
Can 15-PGDH be inhibited to promote tissue repair?
Yes, inhibition of 15-PGDH increases prostaglandin levels and has been shown to rejuvenate aged muscle mass and strength in preclinical models.
What methods are used to measure 15-hydroxyprostaglandin dehydrogenase (NAD+) activity?
Common methods include NADH-coupled spectrophotometric assays, LC-MS/MS lipidomics of PGE2 and 15-keto PGE2, and Western blot for protein levels.
How do CRISPR knockouts help study GO:0016404?
CRISPR knockout of HPGD removes the enzyme activity, allowing researchers to test the consequences of prostaglandin accumulation in cells and animals.
Is 15-PGDH a drug target?
It is considered a potential drug target because modulating its activity can raise or lower prostaglandin tone in conditions such as muscle aging and cancer.
What cell models are available for 15-hydroxyprostaglandin dehydrogenase research?
Knockout, point-mutation, knock-in, and overexpression cell models can be generated to study HPGD function and its role in disease.
Conclusion
GO:0016404, 15-hydroxyprostaglandin dehydrogenase (NAD+) activity, is a central enzymatic function that terminates prostaglandin signaling by oxidizing the 15(S)-hydroxyl group of prostaglandins in an NAD+-dependent manner. Its importance spans muscle aging, tissue repair, bone homeostasis, reproductive biology, and cancer, making it a compelling target for both basic and translational research. CRISPR-based knockout, point-mutation, knock-in, and overexpression models provide powerful tools to dissect the causal roles of HPGD and its regulators in these processes. By combining precise genetic models with biochemical and metabolomic readouts, researchers can advance our understanding of prostaglandin inactivation and develop new therapeutic strategies.
References
- 1. Palla AR et al.. 2021. Inhibition of prostaglandin-degrading enzyme 15-PGDH rejuvenates aged muscle mass and strength.. Science 371(6528) PMID: 33303683
- 2. Ensor CM et al.. 1995. 15-Hydroxyprostaglandin dehydrogenase.. J Lipid Mediat Cell Signal 12(2-3):313-9 PMID: 8777575
- 3. Cheng H et al.. 2021. Role of prostaglandin E2 in tissue repair and regeneration.. Theranostics 11(18):8836-8854 PMID: 34522214
- 4. Sun L et al.. 2023. ENO1 promotes liver carcinogenesis through YAP1-dependent arachidonic acid metabolism.. Nat Chem Biol 19(12):1492-1503 PMID: 37500770
- 5. Tai HH et al.. 2006. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions.. Curr Pharm Des 12(8):955-62 PMID: 16533162
- 6. Casey ML et al.. 1980. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase activity in human endometrium.. Prostaglandins 19(1):115-22 PMID: 7384534
- 7. Chen H et al.. 2019. Prostaglandin E2 mediates sensory nerve regulation of bone homeostasis.. Nat Commun 10(1):181 PMID: 30643142
- 8. Giovannoni F et al.. 2025. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy.. Nat Cancer 6(12):1994-2010 PMID: 41345806
